SCLX (Scilex Holding Co) Growth Rank: 6 (As of Aug. 31, 2026) — 40% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCLX Scilex Holding Co SCLX
57 GF Score
Price $5.36
GF Value $6.35
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co Growth Rank?

Scilex Holding Co SCLX -1.47% 57 Growth Rank is 6 as of Aug. 31, 2026, which is 40% below its 10-year median of 10.00. GuruFocus rates SCLX with a GF Score™ of 57/100 and a GF Value™ of $6.35 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Scilex Holding Co has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Scilex Holding Co Growth Rank Related Terms

SCLX vs MIRA, NSRX, MDCX: Growth Rank Comparison

For the Drug Manufacturers - General subindustry, Scilex Holding Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scilex Holding Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's Growth Rank falls into.


SCLX
57GF Score
Scilex Holding Co SCLX
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 6 mean?
Scilex Holding Co (SCLX) has a Growth Rank of 6 as of Aug. 31, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Scilex Holding Co and its competitors. This is 40% below median its historical median of 10.00. Over the past decade, Scilex Holding Co's Growth Rank has ranged from 6.00 to 10.00.
Is Scilex Holding Co's Growth Rank too high?
Scilex Holding Co's current Growth Rank of 6 is 40% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 10.00. Overall, Scilex Holding Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Growth Rank compare to MIRA and NSRX?
Scilex Holding Co's Growth Rank of 6 can be compared against companies in the Drug Manufacturers industry. Historically, Scilex Holding Co's own Growth Rank has ranged from 6.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Scilex Holding Co and its competitors. Scilex Holding Co's current Growth Rank is 6, which is 40% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.35, compared to a current price of $5.36 — trading 15.6% below its estimated fair value. The current Growth Rank is 6, which is 40% below median its 10-year median of 10.00. Scilex Holding Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current Growth Rank is 6 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scilex Holding Co (SCLX) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be undervalued. The current stock price of $5.36 is trading 15.6% below its estimated GF Value™ of $6.35. GuruFocus considers Scilex Holding Co to be Modestly Undervalued.

Key valuation signals for SCLX:

  • Growth Rank: 6 (40% below median its 10-year median of 10.00)
  • GF Value™: $6.35 vs. price of $5.36 (15.6% below fair value)
  • GF Score™: 57/100 with 7 warning signs

No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scilex Holding Co Business Description

Other Exchanges D8B0:Germany
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
57GF Score

Get the complete analysis for SCLX

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.36
Price
$6.35
GF Value